Stay updated on Neratinib with Trastuzumab in ER+ HER2+ Breast Cancers Clinical Trial
Sign up to get notified when there's something new on the Neratinib with Trastuzumab in ER+ HER2+ Breast Cancers Clinical Trial page.

Latest updates to the Neratinib with Trastuzumab in ER+ HER2+ Breast Cancers Clinical Trial page
- Check7 days agoChange DetectedThe footer now displays Revision: v3.6.2, replacing Revision: v3.6.0, indicating an update to the ClinicalTrials.gov interface.SummaryDifference0.1%

- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedNew navigation links 'Check who can join' and 'Find Contact Information' were added to the page, improving quick access to enrollment and contact details. The release tag now shows 'Revision: v3.6.0' and the previous 'Revision: v3.5.5' tag has been removed.SummaryDifference0.4%

- Check29 days agoChange DetectedRevision: v3.5.5 replaces the previous revision label (v3.5.4) on the study history page, signaling a new version of the page's revision history.SummaryDifference0.1%

- Check50 days agoChange DetectedRevision updated to v3.5.4, indicating a new version of the study record history. This update does not change the underlying study data or trial details.SummaryDifference0.1%

- Check72 days agoChange DetectedThe page’s displayed revision/version number updates from **v3.5.2** to **v3.5.3**, indicating a site release without changing the trial record text.SummaryDifference0.1%

- Check79 days agoChange DetectedAdded Revision: v3.5.2. Removed Revision: v3.5.0.SummaryDifference0.1%

Stay in the know with updates to Neratinib with Trastuzumab in ER+ HER2+ Breast Cancers Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Neratinib with Trastuzumab in ER+ HER2+ Breast Cancers Clinical Trial page.